Stock XVIVO XVIVO PERFUSION AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:47 03/05/2024 BST 		5-day change 1st Jan Change
378 SEK +2.02% Intraday chart for Xvivo Perfusion AB +1.34% +14.72%
04-24 Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
04-24 Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...
AVIS D'ANALYSTES DU JOUR : Kering, Carrefour, STMicroelectronics, ArgenX, Ipsen, Accor, Moncler...
OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas Homes, Almirall, STMicroelectronics, Enagás, Iberdrola, Roche, Temenos, Moncler...
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague
Les actions en mouvement : Vetoquinol et Teleperformance coulent, Vusiongroup et ID Logistics brillent
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee
Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue
Xvivo Perfusion Gets USFDA Nod on Using Donated Hearts in Heart Preservation Clinical Trial
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial
Xvivo Perfusion Closes PrimECC Trial Amid Patient Recruitment Challenges
Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Xvivo Perfusion AB Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated
XVIVO Perfusion AB Enters into A Strategic Collaboration with MTJ Aviation to Strengthen Organ Procurement Services in the US
Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. News Xvivo Perfusion AB
  5. Other languages